Early and late CTCAE and patient-reported outcomes following prostate radiotherapy in the REQUITE cohort.

Authors

Philipp Heumann, Juan Camilo Rosas Romero, Miguel E Aguado Barrera, Ester Aguado Flor, Barbara Avuzzi, David Azria, Erik Briers, Ana Carballo-Castro, Jenny Chang-Claude, Ananya Choudhury, Alison Dunning, Rebecca M Elliott, Laura Fachal, Marie-Pierre Farcy-Jacquet, Antonio Gómez-Caamaño, Sara Gutiérrez-Enríquez, Carsten Herskind, Rudolf Kaaks, Sarah L Kerns, Maarten Lambrecht, Xavier Maldonado, Morgan Michalet, Barbara Noris Chiorda, Paula Peleteiro-Higueiro, Tim Rattay, Barry S Rosenstein, Dirk De Ruysscher, Elena Sperk, Hilary Stobart, R Paul Symonds, Christopher J Talbot, María Aránzazu Tubío-Abuín, Ana Vega, Liv Veldeman, Marlon R Veldwijk, Tim Ward, Adam Webb, Catharine M L West, REQUITE/REQUITEplus/RADprecise consortia, Petra Seibold, Tiziana Rancati

Published in

Clinical and translational radiation oncology. Volume 60. Pages 101219. Epub Jul 02, 2026.

Abstract

Prospectively collected long-term adverse event data with pre-radiotherapy assessment and regular follow-up reflecting 'real world settings' are still limited. Here, we present the available data on early and long-term outcomes up to eight years after radiotherapy in men with prostate cancer who participated in the international REQUITE cohort study, stratified by treatment modalities and patient characteristics.
Longitudinal data on pre-radiotherapy, acute and late symptoms up to eight years after radiotherapy were available from 1760 non-metastatic prostate cancer patients recruited in seven European countries and the USA. External beam radiotherapy (EBRT) and/or brachytherapy were given with curative intent between 2014 and 2016 according to local regimens. Gastrointestinal (GI) and genitourinary (GU) symptoms including sexual dysfunction were prospectively assessed by healthcare professionals according to CTCAE v4.0. Patient-reported outcomes were collected.
The highest incidence of clinician-reported grade ≥ 2 long-term GI and GU symptoms were for proctitis (12.1%) and haematuria (12.9%) among the EBRT-only treated patients, and proctitis (6.4%) and urinary incontinence (32.4%) among the post-prostatectomy/EBRT patients. Incidence of grade 3 adverse events was below 1.5%, with the only exception of late urinary incontinence in post-prostatectomy patients (10.2%).
The frequency and distribution of GI and GU symptoms in a real-world multicentre cohort of patients following prostate radiotherapy were comparable to those reported in large interventional trials. Our finding highlights the value of standardised data farming approaches like the REQUITE project. Most patients consented to provide their data for future cancer research which is available on request.

PMID:
42500362
Bibliographic data and abstract were imported from PubMed on 25 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.